Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SUVOREXANT vs TAFASITAMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

SUVOREXANT vs TAFASITAMAB: Safety Overview

Metric SUVOREXANT TAFASITAMAB
Total FAERS Reports 9,413 1,392
Deaths Reported 219 475
Death Rate 2.3% 34.1%
Hospitalizations 572 433
Average Patient Age 62.6 yrs 70.0 yrs
% Female Patients 62.4% 50.1%
FDA Approval Date Aug 13, 2014 N/A
Manufacturer Merck Sharp & Dohme LLC Incyte Corporation
Route ORAL INTRAVENOUS
Marketing Status Prescription N/A